On the stock market since 2021, it operates in the world of health and science. It has 71 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 100% a year over the last 3 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $574.2M in the vault; even if every debt were paid off, $561.0M would remain.
The average analyst price target is $60.00 — 26% above today’s price.
A loss of $81.7M against $0 in annual sales. And on top of that, sales fell from the year before.
Over the last 12 months, executives reported 53 sells against just 17 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, DICE sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: DICE is a high-risk stock — not yet profitable, and its future rides on its product catching on.